About Soneas
Soneas is a Healthcare company based in Budapest (Hungary) founded in 1996, and was acquired by Uquifa in May 2018. CDMO with expertise in olefine metathesis reactions. Soneas offers products and services including Discovery Process, R&D Services, GMP Manufacturing, and Large Scale Manufacturing. Its focus areas include Biopharma Outsourcing, CDMO, Small Molecules & Peptides and API Production. Its legal entity is Soneas Chemicals Ltd.
Company details
Soneas (formerly known as Ubichem Pharma Group) is a CDMO offering its services for API and intermediate development. The company uses catalytic olefine metathesis, in addition to other traditional manufacturing methods. The companys service portfolio includes process development (including Route selection and safety evaluation, Availability and cost of key raw materials, Process optimisation and scale-up, and Isolation and purification), cGMP API manufacture (Preclinical to commercial supply through kilo labs and pilot plants), Intermediate custom synthesis and manufacture, and analytical support services (Analytical MD MV,Impurities reference standards, Salt screening crystallisation studies, Stability studies). Soneas has a strategic partnership with XiMO AG, a Swiss-based company focused on the development and application of proprietary metathesis catalysts and founded by Richard R. Schrock, the co-winner of 2005 Nobel prize. Metathesis catalysts made up of Molybdenum and Tungsten are cheaper than those made up of Ruthenium and also help in reducing the catalytic load.
- Headquarters Budapest, Hungary
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Website soneas.com
- Social LinkedIn Facebook YouTube
- Acquired by Uquifa (May 2018)
- Legal Name Soneas Chemicals Ltd
- Investors
- Acquired byUquifa
(May 2018)
Products & Services of Soneas
Soneas offers a comprehensive portfolio of products and services, including Discovery Process, R&D Services, GMP Manufacturing, and Large Scale Manufacturing.
Early phase development for chemical projects and trials.
Supports chemistry understanding and innovation processes.
cGMP production of APIs and intermediates for trials.
ISO-certified large-scale chemical manufacturing operations.
Apps and channels of Soneas
its YouTube channel Soneas Chemicals Ltd. has 4 subscribers and 2 videos.
Videos from Soneas
The most watched videos on Soneas's YouTube channel, Soneas Chemicals Ltd. (4 subscribers). Click a video to play it here.
More on Soneas Chemicals Ltd..
Investors in Soneas
Soneas has secured backing from 1 investor. Prominent investors backing the company include UQUIFA Group.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
CDMO company manufacturing APIs and intermediates | 1936 | uquifa.com | Barcelona, Spain |
Investor details for Soneas
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Soneas
2 dated milestones of Soneas across 22 years, from founding to its latest funding, stage changes and deals.
- Founded Soneas is founded.
- Exit Acquired by Uquifa.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Soneas
Complete news archive for Soneas
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Soneas
Soneas was founded in 1996.
Soneas is headquartered in Budapest, Hungary.
Soneas (formerly known as Ubichem Pharma Group) is a CDMO offering its services for API and intermediate development. The company uses catalytic olefine metathesis, in addition to other traditional manufacturing methods. The companys service portfolio includes process development (including Route selection and safety evaluation, Availability and cost of key raw materials, Process optimisation and scale-up, and Isolation and purification), cGMP API manufacture (Preclinical to commercial supply through kilo labs and pilot plants), Intermediate custom synthesis and manufacture, and analytical support services (Analytical MD MV,Impurities reference standards, Salt screening crystallisation studies, Stability studies). Soneas has a strategic partnership with XiMO AG, a Swiss-based company focused on the development and application of proprietary metathesis catalysts and founded by Richard R. Schrock, the co-winner of 2005 Nobel prize. Metathesis catalysts made up of Molybdenum and Tungsten are cheaper than those made up of Ruthenium and also help in reducing the catalytic load.
Soneas offers Discovery Process, R&D Services, GMP Manufacturing, and Large Scale Manufacturing.
Soneas has 1 investor. Key investors include UQUIFA Group.
Soneas operates through Soneas Chemicals Ltd.
Yes. Soneas was acquired by Uquifa in May 2018.